Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-14
2008-12-02
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S201000
Reexamination Certificate
active
07459466
ABSTRACT:
Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines reduce the levels of TNFα in a mammal. A typical embodiment is 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline.
REFERENCES:
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5593990 (1997-01-01), D'Amato
patent: 5629327 (1997-05-01), D'Amato
patent: 5635517 (1997-06-01), Muller et al.
patent: 5698579 (1997-12-01), Muller
patent: 5712291 (1998-01-01), D'Amato
patent: 5798368 (1998-08-01), Muller et al.
patent: 5874448 (1999-02-01), Muller et al.
patent: 5877200 (1999-03-01), Muller
patent: 5929117 (1999-07-01), Muller et al.
patent: 5955476 (1999-09-01), Muller et al.
patent: 6071948 (2000-06-01), D'Amato
patent: 6228879 (2001-05-01), Green et al.
patent: 6281230 (2001-08-01), Muller et al.
patent: 6316471 (2001-11-01), Muller et al.
patent: 6335349 (2002-01-01), Muller et al.
patent: 6358945 (2002-03-01), Breitfelder et al.
patent: 6380239 (2002-04-01), Muller et al.
patent: 6395754 (2002-05-01), Muller et al.
patent: 6403613 (2002-06-01), Man et al.
patent: 6420414 (2002-07-01), D'Amato
patent: 6458810 (2002-10-01), Muller et al.
patent: 6469045 (2002-10-01), D'Amato
patent: 6476052 (2002-11-01), Muller et al.
patent: 6518298 (2003-02-01), Green et al.
patent: 6555554 (2003-04-01), Muller et al.
patent: 6673828 (2004-01-01), Green et al.
patent: 6762195 (2004-07-01), Muller et al.
patent: 6977268 (2005-12-01), D'Amato
patent: 2001/0056114 (2001-12-01), D'Amato
patent: 2002/0045643 (2002-04-01), Muller et al.
patent: 2002/0052398 (2002-05-01), D'Amato
patent: 2002/0054899 (2002-05-01), D'Amato
patent: 2002/0161023 (2002-10-01), D'Amato
patent: 2002/0173658 (2002-11-01), Muller et al.
patent: 2002/0183360 (2002-12-01), Muller et al.
patent: 2003/0028028 (2003-02-01), Man et al.
patent: 2003/0045552 (2003-03-01), Robarge
patent: 2003/0096841 (2003-05-01), Robarge
patent: 2003/0139451 (2003-07-01), Shah et al.
patent: 2003/0144325 (2003-07-01), Muller et al.
patent: 2003/0181428 (2003-09-01), Green et al.
patent: 2003/0187024 (2003-10-01), D'Amato
patent: 2003/0191098 (2003-10-01), D'Amato
patent: 2003/0235909 (2003-12-01), Hariri et al.
patent: 2004/0029832 (2004-02-01), Zeldi
patent: 2004/0077685 (2004-04-01), Figg et al.
patent: 2004/0077686 (2004-04-01), Dannenberg et al.
patent: 2004/0087546 (2004-05-01), Zeldis
patent: 2004/0091455 (2004-05-01), Zeldis
patent: 2004/0122052 (2004-06-01), Muller et al.
patent: 2004/0127545 (2004-07-01), D'Amato et al.
patent: 2004/0147558 (2004-07-01), Treston et al.
patent: 2004/0220144 (2004-11-01), Zeldis
patent: 2005/0096351 (2005-05-01), Jaworsky et al.
patent: 2005/0100529 (2005-05-01), Zeldis
patent: 2005/0143344 (2005-06-01), Zeldis et al.
patent: 2005/0143420 (2005-06-01), Moutouh-de Parseval et al.
patent: 2005/0203142 (2005-09-01), Zeldis et al.
patent: 2005/0214328 (2005-09-01), Zeldis et al.
patent: 2005/0222209 (2005-10-01), Zeldis et al.
patent: WO 94/20085 (1994-09-01), None
patent: WO 98/03502 (1998-01-01), None
patent: WO 98/19649 (1998-05-01), None
patent: WO 98/54170 (1998-12-01), None
patent: WO 01/43743 (2001-06-01), None
patent: WO 02/059106 (2002-08-01), None
patent: WO 02/064083 (2002-08-01), None
patent: WO 03/014315 (2003-02-01), None
patent: WO 03/086373 (2003-10-01), None
patent: WO 03/097052 (2003-11-01), None
patent: WO 2004/035064 (2004-04-01), None
patent: WO 2004/037199 (2004-05-01), None
patent: WO 2004/041190 (2004-05-01), None
patent: WO 2004/043377 (2004-05-01), None
patent: WO 2004/043464 (2004-05-01), None
patent: WO 2004/103274 (2004-12-01), None
patent: WO 2005/023192 (2005-03-01), None
patent: WO 2005/044178 (2005-05-01), None
patent: WO 2005/044259 (2005-05-01), None
patent: WO 2005/046318 (2005-05-01), None
patent: WO 2005/065455 (2005-07-01), None
patent: WO 2005/091991 (2005-10-01), None
patent: WO 2005/097125 (2005-10-01), None
patent: WO 2005/105088 (2005-11-01), None
patent: WO 2005/110408 (2005-11-01), None
patent: WO 2005/112928 (2005-12-01), None
Schmahl et al. “The enantimers of the teratogenic . . . ” CA 110:822 (1989).
Benjamin et al. “A simple on-pot . . . ” CA 2003:522224 (2003).
U.S. Appl. No. 09/287,377, filed Apr. 7, 1999, D'Amato.
U.S. Appl. No. 09/545,654, filed Apr. 10, 2000, D'Amato (submit spec) (9516-116).
U.S. Appl. No. 10/003,461, filed Nov. 30, 2001, Treston et al. (submit spec) (9516-121).
U.S. Appl. No. 10/704,237, filed Nov. 6, 2003, Zeldis (submit spec) (9516-185).
Jonsson, N. Chemical Structure and Teratogenic Properties, Acta. Pharm. Succia, vol. 9, pp. 431-436 (1972).
Jonsson, N., Chemical Structure and Teratogenic Properties, Acta. Pharm. Succia, vol. 9 pp. 521-542 (1972).
Muller, George et al., Structural Modifications of Thalidomide Produce Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity, Journal of Medicinal Chemistry, vol. 39, No. 17, pp. 3238-3240 (1996).
Corral, L. et al., “Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That are Potent Inhibitors of TNF-alpha 1”, The Journal of Immunology, pp. 380-388 (1999).
Corral, L. et al., “Immunomodulation by Thalidomide and Thalidomide Analogues”, Annals of the Rheumatic Diseases, vol. 58, Suppl. 1. pp. 1107-1113 (1999).
Corral, L. et al., “Selection of Novel Analogs of Thalidomide with Enhanced Tumor Necrosis Factor alpha Inhibitory Activity”, Molecular Medicine, vol. 2, No. 4, pp. 506-515 (1996).
He, Weixuan et al., “Synthesis of Thalidomide Analogs and Their Biological Potential for Treatment of Graft Versus Host Disease (GVHD)”, 206thAmerican Chemical Society National Meeting, Med. Chem. Abst. 216 (1993).
Nishimura, K. et al., (S)-Form of alpha-Methyl-N (alpha)-phthalimidoglutarmide but not its (R)- Form, Enhanced Phorbol Ester-induced TNFalpha Production by Human Leukemia Cell HL-60; Implication of Optical Resolution of Thalilomidal Effect, Chem. Pharm. Bull. 42(5), 1157 (1994).
Koch, H., Thalidomide and congeners as Anti-inflammatory Agents, Progress in Medicinal Chemistry, vol. 22. pp. 166-214 (1985).
Miyachi, H. et al., Novel Biological Response Modifiers: Phthalimides with Tumor Necrosis Factor-alpha Production-Regulating Activity, J. Med. Chem., pp. 2858-2865 (1997).
Miyachi, H. et al., Tumor Necrosis Factor-alpha Production Enhancing Activity of Substituted 3′-Methylthalidomide: Influence of Substitutes at the hthaloyl Moiety on the Activity of Steroselectivity, Chem. Pharm. Bull., 46(7), pp. 1165-1168 (1998).
Muller, G. et al., Amino-Substituted Thalidomide Analogs: Potent Inhibitors of TNF-alpha Production, Bioorganic & Medicinal Chem. Letters 9, pp. 1625-1630 (1999).
Miyachi, H. et al., Enantio-Dependence of Inducer-Specific Bidirectional Regulation of Tumor Necrosis Factor (TNF)-alpha Production: Potent TNF-alpha Production Inhibitors, Biorg., Med. Chem. Letter 6(19) 2293 (1996).
Wnendt, S. et al., Enantioselective Inhibition of TNF-alpha Release by Thalidomide and Thalidomide-Analogues, Chirality 8, 390 (1996).
Muller, G. et al., Thlidomide Analogs and PDE4 Inhibition, Bioorganic & Medicinal Chemistry Letters 8, pp. 2669-2674 (1998).
Shannon, E. J., et al., Immunomodulatory Assays to Study Structure-Activity Relationships of Thalidomide, Immunopharmacology 35, pp. 203-212 (1997).
Takeuchi, Y. et al.—and (S)-3-Fluorothalidomides: Isosteric Analogues of Thalidomide, Organic Letters, vol. 1, No. 10, pp. 1571-1573 (1999).
Udagawa, T. et al., Thalidomide and Analogs, Antianglogenic Agents in Cancer Therapy, pp. 263-274.
Chen Roger Shen-Chu
Muller George W.
Stirling David I.
Celgene Corporation
Chang Celia
Jones Day
LandOfFree
Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4038192